Zijian Zeng

Title: Innovations by Zijian Zeng in Bone Resorption Measurement

Introduction

Zijian Zeng is an accomplished inventor based in Warren, NJ (US). He has made significant contributions to the field of biomedical research, particularly in the measurement of bone resorption levels. With a total of 2 patents, his work has the potential to impact clinical practices in monitoring bone health.

Latest Patents

Zijian Zeng's latest patents include a groundbreaking monoclonal antibody known as Serex A93. This antibody recognizes peptide linked pyridinoline in Type I bone collagen fragments, which can be utilized to quantitate bone resorption. The hybridoma producing this antibody has been deposited with the American Type Culture Collection, Rockville, Md., under accession number HB-12254. The epitope reactive with the antibody is stable to acid hydrolysis, indicating that it is not a linear peptide. Notably, the antibody recognizes pyridinoline in bound or conjugated form, but not in the free form found in urine. This innovation is particularly useful in immunoassays for determining bone resorption, utilizing body fluids such as urine, saliva, blood, or sweat.

Career Highlights

Zijian Zeng is currently associated with Serex, Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in clinical diagnostics and therapeutic monitoring.

Collaborations

Zijian has collaborated with notable colleagues, including Judith Fitzpatrick and Regina B Lenda, who have contributed to his research endeavors.

Conclusion

Zijian Zeng's innovative work in the development of antibodies for measuring bone resorption represents a significant advancement in biomedical research. His contributions are poised to enhance the understanding and monitoring of bone health in clinical settings.